Sepsis Diagnostics Market by Technology (Blood Culture, PCR, Immunoassay), Product (Culture, Assay, Instruments), Sample (Serum, blood), Test Type (Lab, POC), Pathogen (Bacterial), End User (Hospital, Pathology & Reference Labs) - Global Forecast to 2031
The sepsis diagnostics market is projected to reach USD 1.22 billion by 2031, up from USD 0.83 billion in 2026, at a CAGR of 7.9%. The global sepsis diagnostics market is expected to grow steadily over the forecast period, driven by the rising burden of sepsis and bloodstream infections, increasing ICU admissions, growing demand for rapid pathogen identification, and rising adoption of molecular diagnostics, automated microbiology platforms, immunoassays, and biomarker-based testing. Market growth is further supported by the increasing focus on antimicrobial stewardship programs, the need to reduce diagnostic turnaround time, and the adoption of automated diagnostic workflows in hospital and reference laboratories. However, the high cost of advanced molecular diagnostic platforms, limited reimbursement for novel diagnostic technologies, the clinical complexity of sepsis presentation, workflow integration challenges, and a shortage of trained laboratory personnel are expected to restrain market growth to some extent.
“Assays & reagent kits accounted for the largest share of the sepsis diagnostics market, by product, in 2025.”
By product, the sepsis diagnostics market is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2025, assays & reagent kits accounted for the largest market share, driven by their recurring use in blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. Rising demand for pathogen detection kits, PCR-based reagents, syndromic testing panels, inflammatory biomarker assays, and sepsis-related consumables continues to support this segment's dominance. Additionally, the growing adoption of automated and molecular testing platforms across hospitals and reference laboratories is further strengthening demand for assays and reagent kits.“Blood culture/microbiology testing accounted for the largest share of the sepsis diagnostics market, by technology, in 2025.”
By technology, the global sepsis diagnostics market is segmented into blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry & blood gas analysis. In 2025, blood culture/microbiology testing accounted for the largest share, reflecting its established role as the standard diagnostic approach for detecting bloodstream infections and supporting antimicrobial susceptibility testing. These technologies are widely used in hospital microbiology laboratories for pathogen detection, organism identification, and therapy guidance. However, molecular diagnostics is expected to grow faster over the forecast period, supported by increasing adoption of PCR/RT-PCR, multiplex PCR panels, microarrays, FISH/PNA-FISH, DNA sequencing, NGS, LAMP, and TMA-based methods for rapid pathogen and resistance marker detection.“The Asia Pacific region is projected to grow at the highest CAGR in the sepsis diagnostics market from 2026 to 2031.”
The sepsis diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, the Asia Pacific region is projected to have the highest CAGR, driven by the rising burden of infectious diseases and bloodstream infections, expanding hospital and ICU infrastructure, rising healthcare expenditure, and growing adoption of automated microbiology and molecular diagnostic platforms. Growth is further supported by improving laboratory capacity, greater awareness of sepsis management, rising demand for rapid diagnostics, and large patient populations across China, Japan, India, South Korea, Australia, and Southeast Asia.List of Companies Profiled in the Report
- Biom?rieux
- Becton Dickinson and Company
- Danaher Corporation
- Diasorin S.P.A (Luminex)
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific, Inc
- Bruker Corporation
- Abbott Laboratories
- Sysmex Corporation
- Siemens Healthineers
- Qiagen
- Quidelortho Corporation
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Research Coverage
This research report categorizes the sepsis diagnostics market by product, technology, method, pathogen type, test type, sample type, complexity, clinical utility/management pathway, end user, and region. The scope of the report covers detailed information on the major factors influencing the market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of key industry players, providing insights into their business overview, product portfolio, key strategies such as product launches, regulatory approvals, collaborations, partnerships, acquisitions, and expansions, as well as recent developments associated with the sepsis diagnostics market. This report also covers a competitive analysis of leading players and emerging companies in the sepsis diagnostics ecosystem.Key Benefits of Buying the Report
The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall sepsis diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses effectively and develop suitable go-to-market strategies. The report will enable stakeholders to understand the market pulse and provide information on key market drivers, restraints, opportunities, and challenges.The report provides insights into the following points
- Analysis of key drivers, including the high incidence of sepsis and bloodstream infections, growing adoption of rapid molecular and syndromic diagnostics, increasing focus on antimicrobial stewardship, and expansion of biomarker-based testing; restraints, including the high cost of advanced molecular diagnostic platforms and limited reimbursement for novel diagnostic technologies; opportunities, including AI-enabled sepsis diagnosis, clinical decision support, next-generation host-response biomarkers, rapid POC testing, and decentralized testing; and challenges, including clinical complexity, heterogeneous sepsis presentation, integration into hospital workflows, and a shortage of trained laboratory personnel
- Product Development/Innovation: Detailed insights into newly launched and emerging sepsis diagnostics products, including automated blood culture systems, molecular diagnostic panels, syndromic testing platforms, immunoassays, biomarker-based tests, mass spectrometry-based microbial identification platforms, antimicrobial susceptibility testing solutions, and AI-enabled clinical decision support tools
- Market Development: Comprehensive information about lucrative markets — the report analyzes the sepsis diagnostics market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with detailed assessment of major country-level opportunities and adoption trends
- Market Diversification: Comprehensive information on product portfolios, technological developments, regulatory approvals, collaborations, partnerships, acquisitions, geographic expansions, and investments in the sepsis diagnostics market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
3.2 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031
3.3 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.4 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2026 VS. 2031
3.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2026 VS. 2031
3.6 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2026 VS. 2031
3.7 SEPSIS DIAGNOSTICS MARKET, SAMPLE TYPE, 2026 VS. 2031
3.8 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2026 VS. 2031
3.9 SEPSIS DIAGNOSTICS MARKET, CLINICAL UTILITY/MANAGEMENT PATHWAY, 2026 VS. 2031
3.10 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031
3.11 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 High incidence of sepsis and bloodstream infections
4.2.1.2 Growing adoption of rapid molecular and syndromic diagnostics
4.2.1.3 Increasing focus on antimicrobial stewardship and expansion of biomarker-based testing for early sepsis detection and risk assessment
4.2.2 RESTRAINTS
4.2.2.1 High cost of advanced molecular diagnostic platforms
4.2.2.2 Limited reimbursement for novel sepsis diagnostic technologies
4.2.3 OPPORTUNITIES
4.2.3.1 AI-enabled sepsis diagnosis and clinical decision support
4.2.3.2 Development of next-generation host-response biomarkers
4.2.3.3 Growth of rapid POC and decentralized testing
4.2.4 CHALLENGES
4.2.4.1 Clinical complexity and heterogeneous presentation of sepsis
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN SEPSIS DIAGNOSTICS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES & STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL SEPSIS DIAGNOSTICS INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 SEPSIS DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 3822)
5.7.2 EXPORT SCENARIO (HS CODE 3822)
5.8 KEY CONFERENCES & EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF US TARIFFS—SEPSIS DIAGNOSTICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGIONS
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Hospital and specialty clinics
5.11.5.2 Pathology and reference laboratories
5.11.5.3 Research laboratories, academic institutes, and CROs
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 HOST-RESPONSE DIAGNOSTICS (TRANSCRIPTOMICS & IMMUNE PROFILING)
6.1.2 AI-ENABLED AND PREDICTIVE SEPSIS DIAGNOSTICS
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING (RAPID AST)
6.2.2 NEXT-GENERATION SEQUENCING (NGS) AND METAGENOMIC SEQUENCING
6.3 ADJACENT TECHNOLOGIES
6.3.1 CONTINUOUS PATIENT MONITORING & CLINICAL DECISION SUPPORT SYSTEMS (CDSS)
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 LIST OF MAJOR PATENTS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON SEPSIS DIAGNOSTICS MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES & MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY ANALYSIS
7.1.1.1 North America
7.1.1.1.1 US
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.2.1 Germany
7.1.1.2.2 UK
7.1.1.2.3 France
7.1.1.2.4 Italy
7.1.1.3 Asia Pacific
7.1.1.3.1 China
7.1.1.3.2 Japan
7.1.1.3.3 India
7.1.1.3.4 Australia
7.1.1.4 Latin America
7.1.1.4.1 Brazil
7.1.1.4.2 Mexico
7.1.1.5 Middle East
7.1.1.5.1 Africa
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
7.2.1.1 Eco-friendly initiatives
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.6 REVENUE POTENTIAL
8.6.1 COST DYNAMICS
9 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 BLOOD CULTURE MEDIA
9.2.1 CONTINUED RELIANCE ON BLOOD CULTURE AS GOLD STANDARD FOR BLOODSTREAM INFECTION DIAGNOSIS SUSTAINS DEMAND
9.3 ASSAYS & REAGENT KITS
9.3.1 INCREASING ADOPTION OF RAPID MOLECULAR AND BIOMARKER-BASED TESTING DRIVES RECURRING DEMAND FOR ASSAYS AND REAGENT KITS
9.4 INSTRUMENTS
9.4.1 EXPANSION OF LAB AUTOMATION AND RAPID DIAGNOSTIC PLATFORMS ACCELERATES INVESTMENT IN ADVANCED INSTRUMENTS
9.5 SOFTWARE
9.5.1 IMPLEMENTATION OF LAB INFORMATICS AND ANTIMICROBIAL STEWARDSHIP SOLUTIONS SUPPORTS SOFTWARE ADOPTION
10 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
10.2.1 AS REGULATORY AND CLINICAL GOLD STANDARD, BLOOD CULTURE HOLDS LARGEST MARKET SHARE
10.3 IMMUNOASSAYS
10.3.1 EXPANDING ADOPTION OF HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS ASSESSMENT AND ANTIMICROBIAL STEWARDSHIP DRIVES MARKET GROWTH
10.4 MOLECULAR DIAGNOSTICS
10.4.1 PCR
10.4.1.1 Widespread hospital adoption of syndromic multiplex panels for rapid pathogen and resistance gene identification to propel market growth
10.4.2 MICROARRAYS
10.4.2.1 Stable utilization in established blood culture identification workflows supports moderate growth
10.4.3 FISH/PNA-FISH
10.4.3.1 Retention of rapid Gram stain-adjunct testing in cost-constrained laboratories sustains low-growth utilization amid progressive substitution
10.4.4 DNA SEQUENCING & NGS
10.4.4.1 Growing clinical interest in culture-independent broad-spectrum pathogen detection drives adoption, constrained by cost and reimbursement barriers
10.4.5 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
10.5 FLOW CYTOMETRY
10.5.1 GROWING CLINICAL INTEREST IN CELLULAR HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS RISK ASSESSMENT SUPPORTS STEADY MARKET GROWTH
10.6 MASS SPECTROMETRY
10.6.1 RISING EMPHASIS ON RAPID DIAGNOSTICS, LAB AUTOMATION, AND ANTIMICROBIAL STEWARDSHIP PROPELS ADOPTION
10.7 CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS
10.7.1 WIDE UTILIZATION OF INFLAMMATORY BIOMARKERS AND RISING ADOPTION OF POC DIAGNOSTICS PROPEL MARKET GROWTH
11 SEPSIS DIAGNOSTICS MARKET, BY METHOD
11.1 INTRODUCTION
11.2 CONVENTIONAL DIAGNOSTICS
11.2.1 RELIANCE ON MANUAL MICROBIOLOGICAL AND BIOCHEMICAL WORKFLOWS IN RESOURCE-CONSTRAINED AND LOW-THROUGHPUT SETTINGS SUSTAINS DEMAND
11.3 AUTOMATED DIAGNOSTICS
11.3.1 GROWING INSTALLATION OF AUTOMATED PLATFORMS TO EXPEDITE TIME-TO-RESULT AND ADDRESS STAFFING SHORTAGES DRIVES SEGMENT GROWTH
12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE
12.1 INTRODUCTION
12.2 BACTERIAL SEPSIS
12.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
12.2.1.1 Rising prevalence of carbapenem-resistant and ESBL-producing organisms driving demand for resistance-marker testing
12.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
12.2.2.1 Established diagnostic workflows for staphylococcal and enterococcal bloodstream infection sustain stable growth
12.3 FUNGAL SEPSIS
12.3.1 RISING INCIDENCE OF FUNGAL BLOODSTREAM INFECTIONS DRIVES DEMAND
12.4 OTHER PATHOGEN TYPES
13 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE
13.1 INTRODUCTION
13.2 LABORATORY TESTS
13.2.1 CENTRALIZATION OF BLOOD CULTURE, MOLECULAR, AND MASS SPECTROMETRY WORKFLOWS WITHIN ACCREDITED HOSPITAL LABORATORIES SUSTAINS THE DOMINANT SHARE
13.3 POC TESTS
13.3.1 EXPANDING NEAR-PATIENT LACTATE AND BIOMARKER TESTING TO MEET SEPSIS BUNDLE COMPLIANCE TIMELINES DRIVES GROWTH
14 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE
14.1 INTRODUCTION
14.2 WHOLE BLOOD
14.2.1 EMERGENCE OF DIRECT-FROM-BLOOD MOLECULAR TESTING AND WIDESPREAD USAGE OF WHOLE BLOOD SPECIMENS DRIVE MARKET
14.3 SERUM
14.3.1 SUSTAINED RELIANCE ON SERUM AND PLASMA FOR BIOMARKER-BASED TRIAGE AND ANTIBIOTIC STEWARDSHIP MAINTAINS STABLE GROWTH
15 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY
15.1 INTRODUCTION
15.2 SINGLEPLEX
15.2.1 RECURRING VOLUME OF SINGLE-ANALYTE BIOMARKER AND CHEMISTRY TESTING SUSTAINS MARKET SHARE
15.3 MULTIPLEX
15.3.1 WIDESPREAD ADOPTION OF SYNDROMIC PANELS DELIVERING SIMULTANEOUS PATHOGEN AND RESISTANCE GENE IDENTIFICATION DRIVES GROWTH
16 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY
16.1 INTRODUCTION
16.2 SEPSIS DIAGNOSIS
16.2.1 EXPANDING AVAILABILITY OF ASSAYS AND WIDESPREAD TESTING TO DRIVE MARKET
16.3 PATHOGEN IDENTIFICATION
16.3.1 ENTRENCHED CULTURE AND IDENTIFICATION WORKFLOWS SUSTAIN SUBSTANTIAL VOLUME
16.4 SEPSIS RISK STRATIFICATION
16.4.1 RISING DEPLOYMENT OF AUTOMATED SEVERITY SCORING AND CELLULAR HOST-RESPONSE MARKERS INTEGRATED WITH EARLY WARNING SYSTEMS DRIVES HIGH GROWTH
16.5 ANTIMICROBIAL STEWARDSHIP SUPPORT
16.5.1 INSTITUTIONAL REQUIREMENT FOR STEWARDSHIP AND ESCALATING BURDEN OF ANTIMICROBIAL RESISTANCE TO DRIVE MARKET
16.6 PROGNOSIS & OUTCOME PREDICTION
16.6.1 LIMITED UTILITY OF PROGNOSTIC INFORMATION CONTINUES TO HINDER DEDICATED ADOPTION
17 SEPSIS DIAGNOSTICS MARKET, BY END USER
17.1 INTRODUCTION
17.2 HOSPITALS & SPECIALTY CLINICS
17.2.1 INCREASING BURDEN OF SEPSIS AND GROWING ADOPTION OF RAPID DIAGNOSTIC WORKFLOWS IN ACUTE CARE SETTINGS TO DRIVE MARKET LEADERSHIP
17.3 PATHOLOGY & REFERENCE LABORATORIES
17.3.1 INCREASING OUTSOURCING OF SPECIALIZED MICROBIOLOGY AND MOLECULAR TESTING SUPPORTS STEADY MARKET GROWTH
17.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS
17.4.1 EXPANDING SEPSIS BIOMARKER RESEARCH AND DIAGNOSTIC INNOVATION CONTINUE TO SUPPORT LONG-TERM MARKET DEVELOPMENT
18 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS)
18.1 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS)
19 SEPSIS DIAGNOSTICS MARKET, BY REGION
19.1 INTRODUCTION
19.2 NORTH AMERICA
19.2.1 US
19.2.1.1 High burden of sepsis and early adoption of advanced diagnostic technologies drive market leadership
19.2.2 CANADA
19.2.2.1 Strong public healthcare infrastructure and expanding adoption of advanced microbiology technologies support market growth
19.3 EUROPE
19.3.1 GERMANY
19.3.1.1 Advanced clinical microbiology infrastructure and strong laboratory automation drive market leadership
19.3.2 UK
19.3.2.1 National sepsis initiatives and NHS investments continue to accelerate adoption of rapid diagnostics
19.3.3 FRANCE
19.3.3.1 Expansion of hospital microbiology networks and leadership of domestic diagnostic manufacturers drive growth
19.3.4 ITALY
19.3.4.1 Growing burden of HAIs supports adoption of advanced sepsis diagnostics
19.3.5 SWITZERLAND
19.3.5.1 Presence of global diagnostic manufacturers and strong healthcare investment support market growth
19.3.6 SPAIN
19.3.6.1 Increasing healthcare modernization and laboratory automation continue to strengthen market growth
19.3.7 REST OF EUROPE
19.4 ASIA PACIFIC
19.4.1 CHINA
19.4.1.1 Rapid healthcare modernization and expanding hospital laboratory infrastructure drive market growth
19.4.2 JAPAN
19.4.2.1 Advanced healthcare infrastructure and high adoption of innovative diagnostics support market expansion
19.4.3 INDIA
19.4.3.1 Expanding healthcare infrastructure and rising sepsis burden accelerate adoption of advanced diagnostics
19.4.4 SOUTH KOREA
19.4.4.1 Government investment in precision medicine and diagnostic innovation drives market expansion
19.4.5 AUSTRALIA
19.4.5.1 Strong clinical guidelines and high adoption of laboratory automation support market growth
19.4.6 REST OF ASIA PACIFIC
19.5 LATIN AMERICA
19.5.1 BRAZIL
19.5.1.1 Growing burden of infectious diseases and expansion of hospital laboratory infrastructure drive market growth
19.5.2 MEXICO
19.5.2.1 Healthcare modernization and expanding access to advanced diagnostics support market growth
19.5.3 REST OF LATIN AMERICA
19.6 MIDDLE EAST & AFRICA
19.6.1 GCC COUNTRIES
19.6.1.1 Healthcare modernization and government investments in advanced diagnostics drive regional growth
19.6.2 REST OF MIDDLE EAST & AFRICA
20 COMPETITIVE LANDSCAPE
20.1 INTRODUCTION
20.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
20.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN SEPSIS DIAGNOSTICS MARKET
20.3 REVENUE ANALYSIS, 2023–2025
20.4 MARKET SHARE ANALYSIS, 2025
20.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
20.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
20.5.1 STARS
20.5.2 EMERGING LEADERS
20.5.3 PERVASIVE PLAYERS
20.5.4 PARTICIPANTS
20.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
20.5.5.1 Company footprint
20.5.5.2 Region footprint
20.5.5.3 Product footprint
20.5.5.4 Technology footprint
20.5.5.5 Pathogen type footprint
20.5.5.6 Test type footprint
20.5.5.7 Method footprint
20.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
20.6.1 PROGRESSIVE COMPANIES
20.6.2 RESPONSIVE COMPANIES
20.6.3 DYNAMIC COMPANIES
20.6.4 STARTING BLOCKS
20.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
20.6.5.1 Detailed list of key startups/SMEs
20.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
20.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
20.7 COMPANY VALUATION & FINANCIAL METRICS
20.7.1 FINANCIAL METRICS
20.7.2 COMPANY VALUATION
20.8 BRAND/PRODUCT COMPARISON
20.9 COMPETITIVE SCENARIO
20.9.1 PRODUCT LAUNCHES & APPROVALS
20.9.2 DEALS
20.9.3 OTHER DEVELOPMENTS
21 COMPANY PROFILES
21.1 KEY PLAYERS
21.1.1 BIOM?RIEUX
21.1.1.1 Business overview
21.1.1.2 Products offered
21.1.1.3 Recent developments
21.1.1.3.1 Product launches & approvals
21.1.1.3.2 Deals
21.1.1.3.3 Other developments
21.1.1.4 MnM view
21.1.1.4.1 Key strengths
21.1.1.4.2 Strategic choices
21.1.1.4.3 Weaknesses & competitive threats
21.1.2 BECTON, DICKINSON AND COMPANY (BD)
21.1.2.1 Business overview
21.1.2.2 Products offered
21.1.2.3 Recent developments
21.1.2.3.1 Product launches & approvals
21.1.2.3.2 Deals
21.1.2.3.3 Other developments
21.1.2.4 MnM view
21.1.2.4.1 Key strengths
21.1.2.4.2 Strategic choices
21.1.2.4.3 Weaknesses and competitive threats
21.1.3 DANAHER
21.1.3.1 Business overview
21.1.3.2 Products offered
21.1.3.3 Recent developments
21.1.3.3.1 Deals
21.1.3.4 MnM view
21.1.3.4.1 Key strengths
21.1.3.4.2 Strategic choices
21.1.3.4.3 Weaknesses & competitive threats
21.1.4 DIASORIN S.P.A.
21.1.4.1 Business overview
21.1.4.2 Products offered
21.1.4.3 Recent developments
21.1.4.3.1 Product launches & approvals
21.1.4.4 MnM view
21.1.4.4.1 Key strengths
21.1.4.4.2 Strategic choices
21.1.4.4.3 Weaknesses & competitive threats
21.1.5 F. HOFFMANN-LA ROCHE LTD.
21.1.5.1 Business overview
21.1.5.2 Products offered
21.1.5.3 Recent developments
21.1.5.3.1 Product launches & approvals
21.1.5.4 MnM view
21.1.5.4.1 Key strengths
21.1.5.4.2 Strategic choices
21.1.5.4.3 Weaknesses & competitive threats
21.1.6 THERMO FISHER SCIENTIFIC INC.
21.1.6.1 Business overview
21.1.6.2 Products offered
21.1.7 BRUKER CORPORATION
21.1.7.1 Business overview
21.1.7.2 Products offered
21.1.7.3 Recent developments
21.1.7.3.1 Product launches & approvals
21.1.7.3.2 Other developments
21.1.8 ABBOTT
21.1.8.1 Business overview
21.1.8.2 Products offered
21.1.9 SYSMEX CORPORATION
21.1.9.1 Business overview
21.1.9.2 Products offered
21.1.9.3 Recent developments
21.1.9.3.1 Deals
21.1.10 SIEMENS HEALTHINEERS AG
21.1.10.1 Business overview
21.1.10.2 Products offered
21.1.11 QIAGEN
21.1.11.1 Business overview
21.1.11.2 Products offered
21.1.11.3 Recent developments
21.1.11.3.1 Product launches & approvals
21.1.12 SEEGENE INC.
21.1.12.1 Business overview
21.1.12.2 Products offered
21.1.12.3 Recent developments
21.1.12.3.1 Product launches & approvals
21.1.13 PHC HOLDINGS CORPORATION
21.1.13.1 Business overview
21.1.13.2 Products offered
21.1.14 QUIDELORTHO CORPORATION
21.1.14.1 Business overview
21.1.14.2 Products offered
21.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
21.1.15.1 Business overview
21.1.15.2 Products offered
21.2 OTHER PLAYERS
21.2.1 EKF DIAGNOSTICS HOLDINGS PLC
21.2.2 INFLAMMATIX, INC.
21.2.3 BODITECH MED INC
21.2.4 ALIFAX S.R.L.
21.2.5 ADVANDX (OPGEN)
21.2.6 FUJIREBIO
21.2.7 IMMUNEXPRESS
21.2.8 RESPONSE BIOMEDICAL CORPORATION
21.2.9 DEEPULL DIAGNOSTICS S.L.
21.2.10 SEKISUI DIAGNOSTICS
22 RESEARCH METHODOLOGY
22.1 RESEARCH DATA
22.2 SECONDARY DATA
22.2.1 LIST OF SECONDARY SOURCES
22.2.2 KEY DATA FROM SECONDARY SOURCES
22.2.3 PRIMARY DATA
22.2.3.1 List of primary sources
22.2.3.2 Key data from primary sources
22.2.3.3 Key industry insights
22.2.3.4 Breakdown of primary interviews
22.3 MARKET SIZE ESTIMATION
22.3.1 TOTAL MARKET SIZE: SEPSIS DIAGNOSTICS MARKET
22.3.2 BOTTOM-UP APPROACH
22.3.2.1 Approach 1: Revenue estimation of key players
22.3.2.2 Approach 2: Study of annual reports and investor presentations
22.3.2.3 Approach 3: Primary interviews
22.3.2.4 Growth forecast
22.3.2.5 CAGR projections
22.3.3 TOP-DOWN APPROACH
22.4 DATA TRIANGULATION
22.5 RESEARCH ASSUMPTIONS
22.5.1 STUDY ASSUMPTIONS
22.5.2 PARAMETRIC ASSUMPTIONS
22.5.3 GROWTH RATE ASSUMPTIONS
22.6 RESEARCH LIMITATIONS
22.7 RISK ASSESSMENT
23 APPENDIX
23.1 DISCUSSION GUIDE
23.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
23.3 CUSTOMIZATION OPTIONS
23.4 RELATED REPORTS
23.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 SEPSIS DIAGNOSTICS MARKET OVERVIEW
3.2 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2026 VS. 2031
3.3 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
3.4 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2026 VS. 2031
3.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2026 VS. 2031
3.6 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2026 VS. 2031
3.7 SEPSIS DIAGNOSTICS MARKET, SAMPLE TYPE, 2026 VS. 2031
3.8 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2026 VS. 2031
3.9 SEPSIS DIAGNOSTICS MARKET, CLINICAL UTILITY/MANAGEMENT PATHWAY, 2026 VS. 2031
3.10 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031
3.11 SEPSIS DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 High incidence of sepsis and bloodstream infections
4.2.1.2 Growing adoption of rapid molecular and syndromic diagnostics
4.2.1.3 Increasing focus on antimicrobial stewardship and expansion of biomarker-based testing for early sepsis detection and risk assessment
4.2.2 RESTRAINTS
4.2.2.1 High cost of advanced molecular diagnostic platforms
4.2.2.2 Limited reimbursement for novel sepsis diagnostic technologies
4.2.3 OPPORTUNITIES
4.2.3.1 AI-enabled sepsis diagnosis and clinical decision support
4.2.3.2 Development of next-generation host-response biomarkers
4.2.3.3 Growth of rapid POC and decentralized testing
4.2.4 CHALLENGES
4.2.4.1 Clinical complexity and heterogeneous presentation of sepsis
4.3 UNMET NEEDS & WHITE SPACES
4.3.1 UNMET NEEDS IN SEPSIS DIAGNOSTICS MARKET
4.3.2 WHITE SPACE OPPORTUNITIES
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5.1 KEY MOVES & STRATEGIC FOCUS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 BARGAINING POWER OF SUPPLIERS
5.1.2 BARGAINING POWER OF BUYERS
5.1.3 THREAT OF NEW ENTRANTS
5.1.4 THREAT OF SUBSTITUTES
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMIC OUTLOOK
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS & FORECAST
5.2.3 TRENDS IN GLOBAL SEPSIS DIAGNOSTICS INDUSTRY
5.3 SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.5.1 SEPSIS DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026
5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024–2026
5.7 TRADE ANALYSIS
5.7.1 IMPORT SCENARIO (HS CODE 3822)
5.7.2 EXPORT SCENARIO (HS CODE 3822)
5.8 KEY CONFERENCES & EVENTS, 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10 INVESTMENT & FUNDING SCENARIO
5.11 IMPACT OF US TARIFFS—SEPSIS DIAGNOSTICS MARKET
5.11.1 INTRODUCTION
5.11.2 KEY TARIFF RATES
5.11.3 PRICE IMPACT ANALYSIS
5.11.4 IMPACT ON REGIONS
5.11.4.1 North America
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 IMPACT ON END-USE INDUSTRIES
5.11.5.1 Hospital and specialty clinics
5.11.5.2 Pathology and reference laboratories
5.11.5.3 Research laboratories, academic institutes, and CROs
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 KEY EMERGING TECHNOLOGIES
6.1.1 HOST-RESPONSE DIAGNOSTICS (TRANSCRIPTOMICS & IMMUNE PROFILING)
6.1.2 AI-ENABLED AND PREDICTIVE SEPSIS DIAGNOSTICS
6.2 COMPLEMENTARY TECHNOLOGIES
6.2.1 RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING (RAPID AST)
6.2.2 NEXT-GENERATION SEQUENCING (NGS) AND METAGENOMIC SEQUENCING
6.3 ADJACENT TECHNOLOGIES
6.3.1 CONTINUOUS PATIENT MONITORING & CLINICAL DECISION SUPPORT SYSTEMS (CDSS)
6.4 TECHNOLOGY/PRODUCT ROADMAP
6.5 PATENT ANALYSIS
6.5.1 LIST OF MAJOR PATENTS
6.6 FUTURE APPLICATIONS
6.7 IMPACT OF AI/GENERATIVE AI ON SEPSIS DIAGNOSTICS MARKET
6.7.1 INTRODUCTION
6.7.2 TOP USE CASES & MARKET POTENTIAL
6.7.3 KEY COMPANIES IMPLEMENTING AI
6.7.4 FUTURE OF AI
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS & COMPLIANCE
7.1.1 REGULATORY ANALYSIS
7.1.1.1 North America
7.1.1.1.1 US
7.1.1.1.2 Canada
7.1.1.2 Europe
7.1.1.2.1 Germany
7.1.1.2.2 UK
7.1.1.2.3 France
7.1.1.2.4 Italy
7.1.1.3 Asia Pacific
7.1.1.3.1 China
7.1.1.3.2 Japan
7.1.1.3.3 India
7.1.1.3.4 Australia
7.1.1.4 Latin America
7.1.1.4.1 Brazil
7.1.1.4.2 Mexico
7.1.1.5 Middle East
7.1.1.5.1 Africa
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES
7.2.1.1 Eco-friendly initiatives
7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
8.5 MARKET PROFITABILITY
8.6 REVENUE POTENTIAL
8.6.1 COST DYNAMICS
9 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 BLOOD CULTURE MEDIA
9.2.1 CONTINUED RELIANCE ON BLOOD CULTURE AS GOLD STANDARD FOR BLOODSTREAM INFECTION DIAGNOSIS SUSTAINS DEMAND
9.3 ASSAYS & REAGENT KITS
9.3.1 INCREASING ADOPTION OF RAPID MOLECULAR AND BIOMARKER-BASED TESTING DRIVES RECURRING DEMAND FOR ASSAYS AND REAGENT KITS
9.4 INSTRUMENTS
9.4.1 EXPANSION OF LAB AUTOMATION AND RAPID DIAGNOSTIC PLATFORMS ACCELERATES INVESTMENT IN ADVANCED INSTRUMENTS
9.5 SOFTWARE
9.5.1 IMPLEMENTATION OF LAB INFORMATICS AND ANTIMICROBIAL STEWARDSHIP SOLUTIONS SUPPORTS SOFTWARE ADOPTION
10 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY
10.1 INTRODUCTION
10.2 BLOOD CULTURE (MICROBIOLOGY TESTING)
10.2.1 AS REGULATORY AND CLINICAL GOLD STANDARD, BLOOD CULTURE HOLDS LARGEST MARKET SHARE
10.3 IMMUNOASSAYS
10.3.1 EXPANDING ADOPTION OF HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS ASSESSMENT AND ANTIMICROBIAL STEWARDSHIP DRIVES MARKET GROWTH
10.4 MOLECULAR DIAGNOSTICS
10.4.1 PCR
10.4.1.1 Widespread hospital adoption of syndromic multiplex panels for rapid pathogen and resistance gene identification to propel market growth
10.4.2 MICROARRAYS
10.4.2.1 Stable utilization in established blood culture identification workflows supports moderate growth
10.4.3 FISH/PNA-FISH
10.4.3.1 Retention of rapid Gram stain-adjunct testing in cost-constrained laboratories sustains low-growth utilization amid progressive substitution
10.4.4 DNA SEQUENCING & NGS
10.4.4.1 Growing clinical interest in culture-independent broad-spectrum pathogen detection drives adoption, constrained by cost and reimbursement barriers
10.4.5 OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES
10.5 FLOW CYTOMETRY
10.5.1 GROWING CLINICAL INTEREST IN CELLULAR HOST-RESPONSE BIOMARKERS FOR EARLY SEPSIS RISK ASSESSMENT SUPPORTS STEADY MARKET GROWTH
10.6 MASS SPECTROMETRY
10.6.1 RISING EMPHASIS ON RAPID DIAGNOSTICS, LAB AUTOMATION, AND ANTIMICROBIAL STEWARDSHIP PROPELS ADOPTION
10.7 CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS
10.7.1 WIDE UTILIZATION OF INFLAMMATORY BIOMARKERS AND RISING ADOPTION OF POC DIAGNOSTICS PROPEL MARKET GROWTH
11 SEPSIS DIAGNOSTICS MARKET, BY METHOD
11.1 INTRODUCTION
11.2 CONVENTIONAL DIAGNOSTICS
11.2.1 RELIANCE ON MANUAL MICROBIOLOGICAL AND BIOCHEMICAL WORKFLOWS IN RESOURCE-CONSTRAINED AND LOW-THROUGHPUT SETTINGS SUSTAINS DEMAND
11.3 AUTOMATED DIAGNOSTICS
11.3.1 GROWING INSTALLATION OF AUTOMATED PLATFORMS TO EXPEDITE TIME-TO-RESULT AND ADDRESS STAFFING SHORTAGES DRIVES SEGMENT GROWTH
12 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE
12.1 INTRODUCTION
12.2 BACTERIAL SEPSIS
12.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
12.2.1.1 Rising prevalence of carbapenem-resistant and ESBL-producing organisms driving demand for resistance-marker testing
12.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
12.2.2.1 Established diagnostic workflows for staphylococcal and enterococcal bloodstream infection sustain stable growth
12.3 FUNGAL SEPSIS
12.3.1 RISING INCIDENCE OF FUNGAL BLOODSTREAM INFECTIONS DRIVES DEMAND
12.4 OTHER PATHOGEN TYPES
13 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE
13.1 INTRODUCTION
13.2 LABORATORY TESTS
13.2.1 CENTRALIZATION OF BLOOD CULTURE, MOLECULAR, AND MASS SPECTROMETRY WORKFLOWS WITHIN ACCREDITED HOSPITAL LABORATORIES SUSTAINS THE DOMINANT SHARE
13.3 POC TESTS
13.3.1 EXPANDING NEAR-PATIENT LACTATE AND BIOMARKER TESTING TO MEET SEPSIS BUNDLE COMPLIANCE TIMELINES DRIVES GROWTH
14 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE
14.1 INTRODUCTION
14.2 WHOLE BLOOD
14.2.1 EMERGENCE OF DIRECT-FROM-BLOOD MOLECULAR TESTING AND WIDESPREAD USAGE OF WHOLE BLOOD SPECIMENS DRIVE MARKET
14.3 SERUM
14.3.1 SUSTAINED RELIANCE ON SERUM AND PLASMA FOR BIOMARKER-BASED TRIAGE AND ANTIBIOTIC STEWARDSHIP MAINTAINS STABLE GROWTH
15 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY
15.1 INTRODUCTION
15.2 SINGLEPLEX
15.2.1 RECURRING VOLUME OF SINGLE-ANALYTE BIOMARKER AND CHEMISTRY TESTING SUSTAINS MARKET SHARE
15.3 MULTIPLEX
15.3.1 WIDESPREAD ADOPTION OF SYNDROMIC PANELS DELIVERING SIMULTANEOUS PATHOGEN AND RESISTANCE GENE IDENTIFICATION DRIVES GROWTH
16 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY
16.1 INTRODUCTION
16.2 SEPSIS DIAGNOSIS
16.2.1 EXPANDING AVAILABILITY OF ASSAYS AND WIDESPREAD TESTING TO DRIVE MARKET
16.3 PATHOGEN IDENTIFICATION
16.3.1 ENTRENCHED CULTURE AND IDENTIFICATION WORKFLOWS SUSTAIN SUBSTANTIAL VOLUME
16.4 SEPSIS RISK STRATIFICATION
16.4.1 RISING DEPLOYMENT OF AUTOMATED SEVERITY SCORING AND CELLULAR HOST-RESPONSE MARKERS INTEGRATED WITH EARLY WARNING SYSTEMS DRIVES HIGH GROWTH
16.5 ANTIMICROBIAL STEWARDSHIP SUPPORT
16.5.1 INSTITUTIONAL REQUIREMENT FOR STEWARDSHIP AND ESCALATING BURDEN OF ANTIMICROBIAL RESISTANCE TO DRIVE MARKET
16.6 PROGNOSIS & OUTCOME PREDICTION
16.6.1 LIMITED UTILITY OF PROGNOSTIC INFORMATION CONTINUES TO HINDER DEDICATED ADOPTION
17 SEPSIS DIAGNOSTICS MARKET, BY END USER
17.1 INTRODUCTION
17.2 HOSPITALS & SPECIALTY CLINICS
17.2.1 INCREASING BURDEN OF SEPSIS AND GROWING ADOPTION OF RAPID DIAGNOSTIC WORKFLOWS IN ACUTE CARE SETTINGS TO DRIVE MARKET LEADERSHIP
17.3 PATHOLOGY & REFERENCE LABORATORIES
17.3.1 INCREASING OUTSOURCING OF SPECIALIZED MICROBIOLOGY AND MOLECULAR TESTING SUPPORTS STEADY MARKET GROWTH
17.4 RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS
17.4.1 EXPANDING SEPSIS BIOMARKER RESEARCH AND DIAGNOSTIC INNOVATION CONTINUE TO SUPPORT LONG-TERM MARKET DEVELOPMENT
18 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS)
18.1 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, (NUMBER OF TESTS IN MILLIONS)
19 SEPSIS DIAGNOSTICS MARKET, BY REGION
19.1 INTRODUCTION
19.2 NORTH AMERICA
19.2.1 US
19.2.1.1 High burden of sepsis and early adoption of advanced diagnostic technologies drive market leadership
19.2.2 CANADA
19.2.2.1 Strong public healthcare infrastructure and expanding adoption of advanced microbiology technologies support market growth
19.3 EUROPE
19.3.1 GERMANY
19.3.1.1 Advanced clinical microbiology infrastructure and strong laboratory automation drive market leadership
19.3.2 UK
19.3.2.1 National sepsis initiatives and NHS investments continue to accelerate adoption of rapid diagnostics
19.3.3 FRANCE
19.3.3.1 Expansion of hospital microbiology networks and leadership of domestic diagnostic manufacturers drive growth
19.3.4 ITALY
19.3.4.1 Growing burden of HAIs supports adoption of advanced sepsis diagnostics
19.3.5 SWITZERLAND
19.3.5.1 Presence of global diagnostic manufacturers and strong healthcare investment support market growth
19.3.6 SPAIN
19.3.6.1 Increasing healthcare modernization and laboratory automation continue to strengthen market growth
19.3.7 REST OF EUROPE
19.4 ASIA PACIFIC
19.4.1 CHINA
19.4.1.1 Rapid healthcare modernization and expanding hospital laboratory infrastructure drive market growth
19.4.2 JAPAN
19.4.2.1 Advanced healthcare infrastructure and high adoption of innovative diagnostics support market expansion
19.4.3 INDIA
19.4.3.1 Expanding healthcare infrastructure and rising sepsis burden accelerate adoption of advanced diagnostics
19.4.4 SOUTH KOREA
19.4.4.1 Government investment in precision medicine and diagnostic innovation drives market expansion
19.4.5 AUSTRALIA
19.4.5.1 Strong clinical guidelines and high adoption of laboratory automation support market growth
19.4.6 REST OF ASIA PACIFIC
19.5 LATIN AMERICA
19.5.1 BRAZIL
19.5.1.1 Growing burden of infectious diseases and expansion of hospital laboratory infrastructure drive market growth
19.5.2 MEXICO
19.5.2.1 Healthcare modernization and expanding access to advanced diagnostics support market growth
19.5.3 REST OF LATIN AMERICA
19.6 MIDDLE EAST & AFRICA
19.6.1 GCC COUNTRIES
19.6.1.1 Healthcare modernization and government investments in advanced diagnostics drive regional growth
19.6.2 REST OF MIDDLE EAST & AFRICA
20 COMPETITIVE LANDSCAPE
20.1 INTRODUCTION
20.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
20.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN SEPSIS DIAGNOSTICS MARKET
20.3 REVENUE ANALYSIS, 2023–2025
20.4 MARKET SHARE ANALYSIS, 2025
20.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
20.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
20.5.1 STARS
20.5.2 EMERGING LEADERS
20.5.3 PERVASIVE PLAYERS
20.5.4 PARTICIPANTS
20.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
20.5.5.1 Company footprint
20.5.5.2 Region footprint
20.5.5.3 Product footprint
20.5.5.4 Technology footprint
20.5.5.5 Pathogen type footprint
20.5.5.6 Test type footprint
20.5.5.7 Method footprint
20.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
20.6.1 PROGRESSIVE COMPANIES
20.6.2 RESPONSIVE COMPANIES
20.6.3 DYNAMIC COMPANIES
20.6.4 STARTING BLOCKS
20.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
20.6.5.1 Detailed list of key startups/SMEs
20.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
20.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
20.7 COMPANY VALUATION & FINANCIAL METRICS
20.7.1 FINANCIAL METRICS
20.7.2 COMPANY VALUATION
20.8 BRAND/PRODUCT COMPARISON
20.9 COMPETITIVE SCENARIO
20.9.1 PRODUCT LAUNCHES & APPROVALS
20.9.2 DEALS
20.9.3 OTHER DEVELOPMENTS
21 COMPANY PROFILES
21.1 KEY PLAYERS
21.1.1 BIOM?RIEUX
21.1.1.1 Business overview
21.1.1.2 Products offered
21.1.1.3 Recent developments
21.1.1.3.1 Product launches & approvals
21.1.1.3.2 Deals
21.1.1.3.3 Other developments
21.1.1.4 MnM view
21.1.1.4.1 Key strengths
21.1.1.4.2 Strategic choices
21.1.1.4.3 Weaknesses & competitive threats
21.1.2 BECTON, DICKINSON AND COMPANY (BD)
21.1.2.1 Business overview
21.1.2.2 Products offered
21.1.2.3 Recent developments
21.1.2.3.1 Product launches & approvals
21.1.2.3.2 Deals
21.1.2.3.3 Other developments
21.1.2.4 MnM view
21.1.2.4.1 Key strengths
21.1.2.4.2 Strategic choices
21.1.2.4.3 Weaknesses and competitive threats
21.1.3 DANAHER
21.1.3.1 Business overview
21.1.3.2 Products offered
21.1.3.3 Recent developments
21.1.3.3.1 Deals
21.1.3.4 MnM view
21.1.3.4.1 Key strengths
21.1.3.4.2 Strategic choices
21.1.3.4.3 Weaknesses & competitive threats
21.1.4 DIASORIN S.P.A.
21.1.4.1 Business overview
21.1.4.2 Products offered
21.1.4.3 Recent developments
21.1.4.3.1 Product launches & approvals
21.1.4.4 MnM view
21.1.4.4.1 Key strengths
21.1.4.4.2 Strategic choices
21.1.4.4.3 Weaknesses & competitive threats
21.1.5 F. HOFFMANN-LA ROCHE LTD.
21.1.5.1 Business overview
21.1.5.2 Products offered
21.1.5.3 Recent developments
21.1.5.3.1 Product launches & approvals
21.1.5.4 MnM view
21.1.5.4.1 Key strengths
21.1.5.4.2 Strategic choices
21.1.5.4.3 Weaknesses & competitive threats
21.1.6 THERMO FISHER SCIENTIFIC INC.
21.1.6.1 Business overview
21.1.6.2 Products offered
21.1.7 BRUKER CORPORATION
21.1.7.1 Business overview
21.1.7.2 Products offered
21.1.7.3 Recent developments
21.1.7.3.1 Product launches & approvals
21.1.7.3.2 Other developments
21.1.8 ABBOTT
21.1.8.1 Business overview
21.1.8.2 Products offered
21.1.9 SYSMEX CORPORATION
21.1.9.1 Business overview
21.1.9.2 Products offered
21.1.9.3 Recent developments
21.1.9.3.1 Deals
21.1.10 SIEMENS HEALTHINEERS AG
21.1.10.1 Business overview
21.1.10.2 Products offered
21.1.11 QIAGEN
21.1.11.1 Business overview
21.1.11.2 Products offered
21.1.11.3 Recent developments
21.1.11.3.1 Product launches & approvals
21.1.12 SEEGENE INC.
21.1.12.1 Business overview
21.1.12.2 Products offered
21.1.12.3 Recent developments
21.1.12.3.1 Product launches & approvals
21.1.13 PHC HOLDINGS CORPORATION
21.1.13.1 Business overview
21.1.13.2 Products offered
21.1.14 QUIDELORTHO CORPORATION
21.1.14.1 Business overview
21.1.14.2 Products offered
21.1.15 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
21.1.15.1 Business overview
21.1.15.2 Products offered
21.2 OTHER PLAYERS
21.2.1 EKF DIAGNOSTICS HOLDINGS PLC
21.2.2 INFLAMMATIX, INC.
21.2.3 BODITECH MED INC
21.2.4 ALIFAX S.R.L.
21.2.5 ADVANDX (OPGEN)
21.2.6 FUJIREBIO
21.2.7 IMMUNEXPRESS
21.2.8 RESPONSE BIOMEDICAL CORPORATION
21.2.9 DEEPULL DIAGNOSTICS S.L.
21.2.10 SEKISUI DIAGNOSTICS
22 RESEARCH METHODOLOGY
22.1 RESEARCH DATA
22.2 SECONDARY DATA
22.2.1 LIST OF SECONDARY SOURCES
22.2.2 KEY DATA FROM SECONDARY SOURCES
22.2.3 PRIMARY DATA
22.2.3.1 List of primary sources
22.2.3.2 Key data from primary sources
22.2.3.3 Key industry insights
22.2.3.4 Breakdown of primary interviews
22.3 MARKET SIZE ESTIMATION
22.3.1 TOTAL MARKET SIZE: SEPSIS DIAGNOSTICS MARKET
22.3.2 BOTTOM-UP APPROACH
22.3.2.1 Approach 1: Revenue estimation of key players
22.3.2.2 Approach 2: Study of annual reports and investor presentations
22.3.2.3 Approach 3: Primary interviews
22.3.2.4 Growth forecast
22.3.2.5 CAGR projections
22.3.3 TOP-DOWN APPROACH
22.4 DATA TRIANGULATION
22.5 RESEARCH ASSUMPTIONS
22.5.1 STUDY ASSUMPTIONS
22.5.2 PARAMETRIC ASSUMPTIONS
22.5.3 GROWTH RATE ASSUMPTIONS
22.6 RESEARCH LIMITATIONS
22.7 RISK ASSESSMENT
23 APPENDIX
23.1 DISCUSSION GUIDE
23.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
23.3 CUSTOMIZATION OPTIONS
23.4 RELATED REPORTS
23.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 4 EUROPE: MACROECONOMIC INDICATORS
TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 8 AVERAGE SELLING PRICE TREND OF SEPSIS DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2024–2026 (USD)
TABLE 9 AVERAGE SELLING PRICE TREND OF SEPSIS DIAGNOSTICS PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 10 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 11 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 12 SEPSIS DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 14 KEY PATENTS IN SEPSIS DIAGNOSTICS MARKET, 2022–2026
TABLE 15 KEY COMPANIES IMPLEMENTING AI IN COMPANION DIAGNOSTICS MARKET
TABLE 16 CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 17 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 18 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT
TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 27 SEPSIS DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 28 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 29 KEY BLOOD CULTURE MEDIA, BY COMPANY
TABLE 30 SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY REGION, 2024–2031 (USD MILLION)
TABLE 31 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 KEY ASSAYS & REAGENT KITS, BY COMPANY
TABLE 37 SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY REGION, 2024–2031 (USD MILLION)
TABLE 38 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 KEY INSTRUMENTS/SYSTEMS, BY COMPANY
TABLE 44 SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 KEY SOFTWARE, BY COMPANY
TABLE 51 SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION)
TABLE 52 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 58 SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY REGION, 2024–2031 (USD MILLION)
TABLE 59 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 77 SEPSIS DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 78 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 114 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 126 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 NORTH AMERICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 EUROPE: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 ASIA PACIFIC: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 LATIN AMERICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 MIDDLE EAST & AFRICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 EUROPE: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 139 BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 LATIN AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 146 GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 NORTH AMERICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 EUROPE: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 ASIA PACIFIC: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 LATIN AMERICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 MIDDLE EAST & AFRICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 153 NORTH AMERICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 EUROPE: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 ASIA PACIFIC: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 LATIN AMERICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 MIDDLE EAST & AFRICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 FUNGAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 NORTH AMERICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 EUROPE: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 LATIN AMERICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY REGION, 2024–2031 (USD MILLION)
TABLE 165 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 171 SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 172 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 184 SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY REGION, 2024–2031 (USD MILLION)
TABLE 191 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 197 SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY REGION, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY REGION, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 210 SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 211 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 217 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 223 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 235 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 241 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 242 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 248 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 250 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2024–2031 (USD MILLION)
TABLE 254 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, 2024–2031 (MILLION TESTS)
TABLE 260 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 261 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 262 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 264 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 265 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 267 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 268 NORTH AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 270 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 271 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 272 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 273 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 274 US: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 275 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 276 US: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 277 US: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 278 US: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 279 US: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280 US: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 281 US: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 282 US: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 283 US: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 284 US: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 285 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 286 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 287 CANADA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288 CANADA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 289 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 290 CANADA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 291 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 292 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 293 CANADA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 294 CANADA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 295 CANADA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 296 EUROPE: MACROECONOMIC INDICATORS
TABLE 297 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 299 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 300 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 302 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 303 EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 304 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 305 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 306 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 307 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 308 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 309 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 310 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 311 GERMANY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 313 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 314 GERMANY: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 315 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 316 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 317 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 318 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 319 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 320 UK: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 321 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 322 UK: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 323 UK: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 324 UK: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 325 UK: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 326 UK: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 327 UK: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 328 UK: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 329 UK: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 1 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030
TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 4 EUROPE: MACROECONOMIC INDICATORS
TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS
TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS
TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
TABLE 8 AVERAGE SELLING PRICE TREND OF SEPSIS DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2024–2026 (USD)
TABLE 9 AVERAGE SELLING PRICE TREND OF SEPSIS DIAGNOSTICS PRODUCTS, BY REGION, 2024–2026 (USD)
TABLE 10 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 11 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION)
TABLE 12 SEPSIS DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
TABLE 13 US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 14 KEY PATENTS IN SEPSIS DIAGNOSTICS MARKET, 2022–2026
TABLE 15 KEY COMPANIES IMPLEMENTING AI IN COMPANION DIAGNOSTICS MARKET
TABLE 16 CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 17 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 18 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
TABLE 19 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 23 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
TABLE 25 KEY BUYING CRITERIA, BY PRODUCT
TABLE 26 ADOPTION BARRIERS & INTERNAL CHALLENGES
TABLE 27 SEPSIS DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
TABLE 28 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 29 KEY BLOOD CULTURE MEDIA, BY COMPANY
TABLE 30 SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY REGION, 2024–2031 (USD MILLION)
TABLE 31 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 32 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 34 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE MEDIA, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36 KEY ASSAYS & REAGENT KITS, BY COMPANY
TABLE 37 SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY REGION, 2024–2031 (USD MILLION)
TABLE 38 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 39 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 41 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR ASSAYS & REAGENT KITS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43 KEY INSTRUMENTS/SYSTEMS, BY COMPANY
TABLE 44 SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 45 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 46 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 48 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50 KEY SOFTWARE, BY COMPANY
TABLE 51 SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY REGION, 2024–2031 (USD MILLION)
TABLE 52 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 53 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 55 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SOFTWARE, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 58 SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY REGION, 2024–2031 (USD MILLION)
TABLE 59 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 60 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 62 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR BLOOD CULTURE (MICROBIOLOGY TESTING), BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64 SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 65 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 67 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70 SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 71 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 74 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 76 SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 77 SEPSIS DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION)
TABLE 78 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 81 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 83 SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY REGION, 2024–2031 (USD MILLION)
TABLE 84 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MICROARRAYS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY REGION, 2024–2031 (USD MILLION)
TABLE 90 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 91 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR FISH/PNA-FISH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY REGION, 2024–2031 (USD MILLION)
TABLE 96 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 98 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR DNA SEQUENCING & NGS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101 SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 102 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 105 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107 SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 108 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 110 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 113 SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY REGION, 2024–2031 (USD MILLION)
TABLE 114 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 118 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119 SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 120 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY & BLOOD GAS ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 125 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 126 CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 127 NORTH AMERICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128 EUROPE: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129 ASIA PACIFIC: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130 LATIN AMERICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131 MIDDLE EAST & AFRICA: CONVENTIONAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 133 NORTH AMERICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 134 EUROPE: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135 ASIA PACIFIC: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136 LATIN AMERICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: AUTOMATED SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 139 BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 140 NORTH AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 141 EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 142 ASIA PACIFIC: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143 LATIN AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144 MIDDLE EAST & AFRICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145 BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 146 GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 147 NORTH AMERICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148 EUROPE: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 149 ASIA PACIFIC: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150 LATIN AMERICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151 MIDDLE EAST & AFRICA: GRAM-NEGATIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152 GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 153 NORTH AMERICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 154 EUROPE: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155 ASIA PACIFIC: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 156 LATIN AMERICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157 MIDDLE EAST & AFRICA: GRAM-POSITIVE BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158 FUNGAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 159 NORTH AMERICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160 EUROPE: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 161 ASIA PACIFIC: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162 LATIN AMERICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 163 MIDDLE EAST & AFRICA: FUNGAL SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 164 SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY REGION, 2024–2031 (USD MILLION)
TABLE 165 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 169 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR OTHER PATHOGEN TYPES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 171 SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 172 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 177 SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY REGION, 2024–2031 (USD MILLION)
TABLE 178 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 179 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR POC TESTS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183 SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 184 SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY REGION, 2024–2031 (USD MILLION)
TABLE 185 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 186 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR WHOLE BLOOD, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190 SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY REGION, 2024–2031 (USD MILLION)
TABLE 191 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 193 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SERUM, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196 SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 197 SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY REGION, 2024–2031 (USD MILLION)
TABLE 198 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 200 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SINGLEPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203 SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY REGION, 2024–2031 (USD MILLION)
TABLE 204 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 205 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 207 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 208 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR MULTIPLEX, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209 SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 210 SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 211 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 213 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 215 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 217 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 220 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOGEN IDENTIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 222 SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY REGION, 2024–2031 (USD MILLION)
TABLE 223 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 227 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR SEPSIS RISK STRATIFICATION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228 SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY REGION, 2024–2031 (USD MILLION)
TABLE 229 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR ANTIMICROBIAL STEWARDSHIP SUPPORT, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 234 SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY REGION, 2024–2031 (USD MILLION)
TABLE 235 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 236 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 237 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PROGNOSIS & OUTCOME PREDICTION, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 241 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2031 (USD MILLION)
TABLE 242 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 244 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 248 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 249 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 250 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 251 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY REGION, 2024–2031 (USD MILLION)
TABLE 254 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 256 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 257 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 258 MIDDLE EAST & AFRICA: SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, ACADEMIC INSTITUTES, AND CROS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259 SEPSIS DIAGNOSTICS MARKET VOLUME ANALYSIS, BY REGION, 2024–2031 (MILLION TESTS)
TABLE 260 SEPSIS DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 261 NORTH AMERICA: MACROECONOMIC INDICATORS
TABLE 262 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 263 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 264 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 265 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 266 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 267 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 268 NORTH AMERICA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 270 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 271 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 272 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 273 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 274 US: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 275 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 276 US: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 277 US: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 278 US: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 279 US: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 280 US: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 281 US: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 282 US: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 283 US: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 284 US: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 285 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 286 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 287 CANADA: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288 CANADA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 289 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 290 CANADA: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 291 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 292 CANADA: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 293 CANADA: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 294 CANADA: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 295 CANADA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 296 EUROPE: MACROECONOMIC INDICATORS
TABLE 297 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 298 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 299 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 300 EUROPE: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 301 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 302 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 303 EUROPE: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 304 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 305 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 306 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 307 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 308 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 309 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 310 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 311 GERMANY: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 313 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 314 GERMANY: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 315 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 316 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 317 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 318 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
TABLE 319 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 320 UK: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2024–2031 (USD MILLION)
TABLE 321 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
TABLE 322 UK: SEPSIS DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 323 UK: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
TABLE 324 UK: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN TYPE, 2024–2031 (USD MILLION)
TABLE 325 UK: BACTERIAL SEPSIS DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 326 UK: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2024–2031 (USD MILLION)
TABLE 327 UK: SEPSIS DIAGNOSTICS MARKET, BY PLEXITY, 2024–2031 (USD MILLION)
TABLE 328 UK: SEPSIS DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION)
TABLE 329 UK: SEPSIS DIAGNOSTICS MARKET, BY CLINICAL UTILITY/MANAGEMENT PATHWAY, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 SEPSIS DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS
FIGURE 3 GLOBAL SEPSIS DIAGNOSTICS MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN SEPSIS DIAGNOSTICS MARKET, 2023–2025
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF SEPSIS DIAGNOSTICS MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN SEPSIS DIAGNOSTICS MARKET, 2025
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 8 INCREASING ADOPTION OF TARGETED THERAPIES TO DRIVE MARKET
FIGURE 9 ASSAYS & REAGENT KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 10 BLOOD CULTURE (MICROBIOLOGY TESTING) SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 11 AUTOMATED DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 12 BACTERIAL SEPSIS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13 LABORATORY TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 WHOLE BLOOD SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 15 SINGLEPLEX SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 16 SEPSIS DIAGNOSIS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 17 HOSPITALS & SPECIALTY CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 20 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 21 SEPSIS DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 22 SEPSIS DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 23 SEPSIS DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 24 SEPSIS DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 25 DEALS & FUNDING ACTIVITIES IN SEPSIS DIAGNOSTICS MARKET
FIGURE 26 PATENT ANALYSIS FOR SEPSIS DIAGNOSTICS MARKET, JANUARY 2016–DECEMBER 2025
FIGURE 27 MARKET POTENTIAL OF AI IN SEPSIS DIAGNOSTICS MARKET
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 29 KEY BUYING CRITERIA, BY PRODUCT
FIGURE 30 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
FIGURE 31 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN SEPSIS DIAGNOSTICS MARKET, 2023–2025 (USD MILLION)
FIGURE 33 SEPSIS DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
FIGURE 34 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 35 SEPSIS DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 36 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 37 EV/EBITDA OF KEY VENDORS
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 39 SEPSIS DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR SEPSIS DIAGNOSTICS
FIGURE 40 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 41 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025)
FIGURE 42 DANAHER: COMPANY SNAPSHOT (2025)
FIGURE 43 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 47 ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 49 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
FIGURE 50 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 51 SEEGENE INC.: COMPANY SNAPSHOT (2025)
FIGURE 52 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 55 RESEARCH DESIGN
FIGURE 56 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 57 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030): IMPACT ON MARKET GROWTH AND CAGR
FIGURE 58 TOP-DOWN APPROACH
FIGURE 59 DATA TRIANGULATION
FIGURE 1 SEPSIS DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS
FIGURE 3 GLOBAL SEPSIS DIAGNOSTICS MARKET, 2024–2031
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN SEPSIS DIAGNOSTICS MARKET, 2023–2025
FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF SEPSIS DIAGNOSTICS MARKET
FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN SEPSIS DIAGNOSTICS MARKET, 2025
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 8 INCREASING ADOPTION OF TARGETED THERAPIES TO DRIVE MARKET
FIGURE 9 ASSAYS & REAGENT KITS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 10 BLOOD CULTURE (MICROBIOLOGY TESTING) SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 11 AUTOMATED DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 12 BACTERIAL SEPSIS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 13 LABORATORY TESTS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 14 WHOLE BLOOD SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 15 SINGLEPLEX SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 16 SEPSIS DIAGNOSIS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 17 HOSPITALS & SPECIALTY CLINICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 20 SEPSIS DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 21 SEPSIS DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 22 SEPSIS DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
FIGURE 23 SEPSIS DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
FIGURE 24 SEPSIS DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 25 DEALS & FUNDING ACTIVITIES IN SEPSIS DIAGNOSTICS MARKET
FIGURE 26 PATENT ANALYSIS FOR SEPSIS DIAGNOSTICS MARKET, JANUARY 2016–DECEMBER 2025
FIGURE 27 MARKET POTENTIAL OF AI IN SEPSIS DIAGNOSTICS MARKET
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
FIGURE 29 KEY BUYING CRITERIA, BY PRODUCT
FIGURE 30 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
FIGURE 31 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN SEPSIS DIAGNOSTICS MARKET, 2023–2025 (USD MILLION)
FIGURE 33 SEPSIS DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
FIGURE 34 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 35 SEPSIS DIAGNOSTICS MARKET: COMPANY FOOTPRINT
FIGURE 36 SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 37 EV/EBITDA OF KEY VENDORS
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 39 SEPSIS DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR SEPSIS DIAGNOSTICS
FIGURE 40 BIOM?RIEUX: COMPANY SNAPSHOT (2025)
FIGURE 41 BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT (2025)
FIGURE 42 DANAHER: COMPANY SNAPSHOT (2025)
FIGURE 43 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
FIGURE 44 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025)
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 47 ABBOTT: COMPANY SNAPSHOT (2025)
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 49 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025)
FIGURE 50 QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 51 SEEGENE INC.: COMPANY SNAPSHOT (2025)
FIGURE 52 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 53 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2025)
FIGURE 54 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2025)
FIGURE 55 RESEARCH DESIGN
FIGURE 56 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 57 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030): IMPACT ON MARKET GROWTH AND CAGR
FIGURE 58 TOP-DOWN APPROACH
FIGURE 59 DATA TRIANGULATION
More Publications
Molecular Diagnostics Market (By Application, Technology, Region and Companies) and Forecast to 2021 - Global Analysis
US$ 1,100.00
September 2016
149 pages
2016 U.S. Automated Microbiology Market: Supplier Shares, Country Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies-Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics
US$ 7,880.00
November 2015
436 pages
2016 France Automated Microbiology Market: Supplier Shares, Country Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies-Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics
US$ 5,560.00
November 2015
423 pages
2016 Germany Automated Microbiology Market: Supplier Shares, Country Forecasts, Innovative Technologies, Instrumentation Review, Competitive Strategies-Molecular Diagnostics, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics
US$ 5,560.00
November 2015
420 pages
